Follow
Vanessa Merker
Vanessa Merker
Massachusetts General Hospital
Verified email at mgh.harvard.edu - Homepage
Title
Cited by
Cited by
Year
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients
SR Plotkin, VL Merker, C Halpin, D Jennings, MJ McKenna, GJ Harris, ...
Otology & Neurotology 33 (6), 1046-1052, 2012
2432012
Clinical features of schwannomatosis: a retrospective analysis of 87 patients
VL Merker, S Esparza, MJ Smith, A Stemmer-Rachamimov, SR Plotkin
The oncologist 17 (10), 1317-1322, 2012
2102012
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis
SR Plotkin, MA Bredella, W Cai, A Kassarjian, GJ Harris, S Esparza, ...
PloS one 7 (4), e35711, 2012
1622012
Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2–associated vestibular schwannomas
JO Blakeley, X Ye, DG Duda, CF Halpin, AL Bergner, A Muzikansky, ...
Journal of Clinical Oncology 34 (14), 1669, 2016
1112016
Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients
FP Nunes, VL Merker, D Jennings, PA Caruso, E di Tomaso, ...
PLoS One 8 (3), e59941, 2013
1092013
Understanding relationships between autism, intelligence, and epilepsy: a cross‐disorder approach
AM Van Eeghen, MB Pulsifer, VL Merker, AM Neumeyer, EE Van Eeghen, ...
Developmental Medicine & Child Neurology 55 (2), 146-153, 2013
1082013
Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature
AM Vranceanu, VL Merker, E Park, SR Plotkin
Journal of neuro-oncology 114, 257-262, 2013
1042013
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation
SR Plotkin, L Messiaen, E Legius, P Pancza, RA Avery, JO Blakeley, ...
Genetics in Medicine 24 (9), 1967-1977, 2022
822022
Mind–body therapy via videoconferencing in patients with neurofibromatosis: An RCT
AM Vranceanu, E Riklin, VL Merker, EA Macklin, ER Park, SR Plotkin
Neurology 87 (8), 806-814, 2016
812016
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
KM Slusarz, VL Merker, A Muzikansky, SA Francis, SR Plotkin
Cancer chemotherapy and pharmacology 73, 1197-1204, 2014
812014
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients
SR Plotkin, VL Merker, A Muzikansky, FG Barker, W Slattery III
Otology & Neurotology 35 (1), e50-e56, 2014
712014
Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature
AM Vranceanu, VL Merker, ER Park, SR Plotkin
Journal of neuro-oncology 122, 219-228, 2015
632015
The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study
AM Vranceanu, VL Merker, SR Plotkin, ER Park
Journal of Neuro-oncology 120, 103-109, 2014
632014
Relationship between whole‐body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis
VL Merker, MA Bredella, W Cai, A Kassarjian, GJ Harris, A Muzikansky, ...
American Journal of Medical Genetics Part A 164 (6), 1431-1437, 2014
592014
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials
PL Wolters, S Martin, VL Merker, JH Tonsgard, SE Solomon, A Baldwin, ...
Neurology 87 (7_Supplement_1), S4-S12, 2016
502016
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2
S Farschtschi, VL Merker, D Wolf, M Schuhmann, J Blakeley, SR Plotkin, ...
Acta Neurologica Scandinavica 133 (6), 475-480, 2016
502016
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials
PL Wolters, S Martin, VL Merker, KL Gardner, CM Hingtgen, JH Tonsgard, ...
Neurology 81 (21_supplement_1), S6-S14, 2013
492013
Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis
JL Jaremko, PJ MacMahon, M Torriani, VL Merker, VF Mautner, ...
Skeletal Radiology, 1-7, 2011
422011
Pain correlates with germline mutation in schwannomatosis
JT Jordan, MJ Smith, JA Walker, S Erdin, ME Talkowski, VL Merker, ...
Medicine 97 (5), e9717, 2018
282018
Health-related quality of life of individuals with neurofibromatosis type 2: results from the NF2 natural history study
VL Merker, AL Bergner, AM Vranceanu, A Muzikansky, W Slattery III, ...
Otology & Neurotology 37 (5), 574-579, 2016
282016
The system can't perform the operation now. Try again later.
Articles 1–20